Sobi将在 EULAR 2025分享新的临床数据和研究成果-动脉网

Sobi to share new clinical data and research at EULAR 2025

CISION 等信源发布 2025-05-28 15:15



可切换为仅中文







STOCKHOLM

斯德哥尔摩

，

May 28, 2025

2025年5月28日

/PRNewswire/ -- Sobi® (STO: SOBI) will present new clinical data and research outcomes at the annual European Congress of Rheumatology (EULAR 2025) in

/PRNewswire/ -- Sobi®（STO：SOBI）将在年度欧洲风湿病学大会（EULAR 2025）上展示新的临床数据和研究成果。

Barcelona

巴塞罗那

from the

来自

11-14 June 2025

2025年6月11日至14日

. Research will include clinical trial outcomes on the efficacy and safety of Gamifant in the treatment of macrophage activating syndrome, updates on trial details of Vonjo investigating the potential treatment of VEXAS, and an analysis on the management of uncontrolled gout.

研究将包括Gamifant治疗巨噬细胞活化综合征的临床试验结果，关于Vonjo在研VEXAS潜在治疗的试验详情更新，以及对失控性痛风管理的分析。

Sobi will host a symposium on the dermatologic, rheumatologic, and hematologic features of VEXAS syndrome during the congress. The symposium will be chaired by Dr Sophie Georgin-Lavialle MD, PhD from the French National Reference Centre for auto-inflammatory diseases and inflammatory amyloidosis. The symposium will be followed by a panel discussion and Q&A..

Sobi将在大会期间举办关于VEXAS综合征的皮肤、风湿和血液特征的研讨会。研讨会将由法国国家自体炎症性疾病和炎症性淀粉样变参考中心的Sophie Georgin-Lavialle医学博士主持。研讨会之后将进行小组讨论和问答环节。

'We are delighted that our continued advancements in treating rare disease, including those suffering with the most debilitating rheumatology conditions will be presented at this year's EULAR conference. Sobi's presentations will provide insights and treatment options for those working with patients with rheumatological conditions, providing them with the most up-to-date clinical data and approaches,' said .

“我们很高兴我们在治疗罕见疾病方面的持续进展，包括那些患有最严重风湿病的患者，将在今年的EULAR会议上展示。Sobi的报告将为从事风湿病患者工作的人员提供见解和治疗选择，向他们提供最新临床数据和方法，”他表示。

Lydia Abad-Franch

莉迪亚·阿巴德-弗朗什

, MD, MBA, Head of Research, Development, and Medical Affairs (RDMA), and Chief Medical Officer at Sobi.

医学博士，工商管理硕士，Sobi公司研发与医疗事务（RDMA）部门负责人，首席医学官。

'With several poster and oral presentations and a longer form symposium, we are proud to be able to show how research and collaboration can advance clinical practice – and we look forward to meeting and connecting with colleagues in

“通过多场海报展示、口头报告以及更长形式的研讨会，我们自豪地展示了研究与合作如何推动临床实践的发展——我们期待与各位同事见面并建立联系。

Barcelona

巴塞罗那

，

Lydia Abad-Franch

莉迪亚·阿巴德-弗朗什

concluded.

已结束。

Key data to be presented at EULAR 2025

EULAR 2025 将展示的关键数据

Gamifant (emapalumab)

Gamifant（依帕鲁单抗）

Efficacy and Safety of emapalumab in Patients with Macrophage Activation Syndrome in Still's disease: Results from a Pooled Analysis of Two Prospective Trials

emapalumab治疗Still病中巨噬细胞活化综合征患者的疗效与安全性：两项前瞻性试验的汇总分析结果

Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)

讲者：法布里齐奥·德贝内代蒂教授（该研究的首席研究员）

Oral presentation

口头报告

Session title:

会议标题：

Clinical Abstract Session: Proceedings in Juvenile Idiopathic Arthritis

临床摘要会议：幼年特发性关节炎的进展

Session date: Thursday 12 June

会议日期：6月12日星期四

Session time: 10:30 - 12:00 CEST

会议时间：10:30 - 12:00 中欧夏令时间

Presentation time: 10:48 - 10:57 CEST

演示时间：10:48 - 10:57 CEST

Location: Room 6.1

地点：6.1房间

Exposure-safety analysis from two clinical trials of emapalumab in patients with macrophage activation syndrome in Still's disease

两项依马利珠单抗在Still病相关巨噬细胞活化综合征患者中的临床试验的暴露-安全性分析

Speaker: Professor Fabrizio De Benedetti (principal investigator of the study)

讲者：法布里齐奥·德贝内代蒂教授（研究的首席研究员）

Poster presentation

海报展示

Session title:

会议标题：

Poster View VI

海报视图 VI

Session date: Friday 13 June

会议日期：6月13日星期五

Session time: 12:00 – 13:30 CEST

会议时间：12:00 – 13:30 中欧夏令时间

Location: Poster Hall

地点：海报大厅

NASP (formerly SEL-212)

NASP（原SEL-212）

Variations in uncontrolled gout between Rheumatologists and Nephrologists

风湿病学家和肾病学家在未控制的痛风方面的差异

Poster presentation

海报展示

Session title:

会议标题：

Poster View VIII

海报视图 VIII

Session date: Friday 13 June

会议日期：6月13日星期五

Session time: 10:15 - 11:45 CEST

会议时间：10:15 - 11:45 欧洲中部夏令时间

Location: Poster Hall

地点：海报大厅

Vonjo (pacritinib)

冯乔（帕克替尼）

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

制定用于临床研究的VEXAS复发共识定义

Poster presentation

海报展示

Session title:

会议标题：

Poster View VII

海报视图 VII

Session date: Friday 13 June

会议日期：6月13日星期五

Session time: 14 :45 - 15 :45 CEST

会议时间：14:45 - 15:45 欧洲中部夏令时间

Location: Poster Hall

地点：海报大厅

PAXIS: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Phase 2 Study (Part 1) Followed by an Open-Label Period (Part 2) to Assess the Efficacy and Safety of Pacritinib in Patients with VEXAS Syndrome

PAXIS：一项随机、双盲、安慰剂对照的2期剂量探索研究（第1部分），随后为开放标签期（第2部分），评估Pacritinib在VEXAS综合征患者中的疗效与安全性。

Poster tour

海报之旅

Session Title:

会议标题：

Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS

海报巡展 II/临床与基础海报巡展：包括 VEXAS 在内的自身炎症性疾病

Session date: Saturday 14 June

会议日期：6月14日星期六

Session time: 10:15 -11:45 CEST

会议时间：10:15 - 11:45 中欧夏令时

Presentation time: 10:29 - 10:36 CEST (4 mins + 2 mins Q&A)

演讲时间：10:29 - 10:36 CEST（4分钟演讲 + 2分钟问答）

Location: Poster Tour II

位置：海报巡回II

Development of a Disease Activity Index for the Assessment of VEXAS Syndrome (VEXAS-DAI)

VEXAS综合征评估的疾病活动指数的开发（VEXAS-DAI）

Poster tour

海报之旅

Session title:

会议标题：

Poster Tour II/ Clinical and Basic Poster Tours: Autoinflammatory Diseases including VEXAS

海报巡展 II/ 临床与基础海报巡展：包括 VEXAS 在内的自身炎症性疾病

Session date: Saturday 14 June

会议日期：6月14日，星期六

Session time: 10:15 - 11:45 CEST

会议时间：10:15 - 11:45 欧洲中部夏令时间

Presentation time: 10:43 - 10:50 CEST (4 mins + 2 mins Q&A)

展示时间：10:43 - 10:50 CEST（4分钟演讲 + 2分钟问答）

Location: Poster Tour II

位置：海报巡回II

Medical Symposium

医学研讨会

An in-depth presentation on VEXAS syndrome: the dermatologic, rheumatologic, and hematologic features of the condition. Followed by a panel discussion and Q&A

关于VEXAS综合征的深入报告：该疾病的皮肤、风湿和血液学特征。随后进行小组讨论和问答环节。

Symposium title:

研讨会标题：

Putting on your VEXAS goggles: Seeing what's in plain sight

戴上你的VEXAS护目镜：看清眼前的一切

Session date: Friday 13 June

会议日期：6月13日星期五

Session time: 17:30 - 18:30 CEST

会议时间：17:30 - 18:30 中欧夏令时间（CEST）

Location: Fira de Barcelona, Room B4

地点：巴塞罗那菲拉，B4室

About Gamifant

关于Gamifant

(emapalumab)

Gamifant

(emapalumab) is indicated for the treatment of adult and paediatric (newborn and older) patients with primary

(emapalumab) 适用于治疗成人和儿童（新生儿及以上）的原发性患者

hemophagocytic lymphohistiocytosis (HLH)

噬血细胞性淋巴组织细胞增多症 (HLH)

with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.

伴有难治性、复发性或进展性疾病，或对常规HLH治疗不耐受。

About Macrophage activation syndrome (MAS)

关于巨噬细胞活化综合征 (MAS)

Macrophage activation syndrome (MAS) is a potentially life-threatening complication of Still's disease characterised by interferon-gamma (IFNγ)–driven systemic hyperinflammation. More than one-third of patients inadequately respond to high-dose glucocorticoids. Emapalumab, an anti-IFNγ antibody, demonstrated efficacy and safety in a phase 2 pilot study in patients with MAS in Still's disease and an inadequate response to high-dose glucocorticoids..

巨噬细胞活化综合征 (MAS) 是 Still 病的一种可能危及生命的并发症，其特征为干扰素-γ (IFNγ) 引发的全身性过度炎症。超过三分之一的患者对高剂量糖皮质激素反应不足。Emapalumab 是一种抗 IFNγ 抗体，在一项针对 Still 病相关 MAS 且对高剂量糖皮质激素反应不佳患者的 2 期试点研究中展示了有效性和安全性。

About NASP, formerly SEL-212

关于NASP，原SEL-212

NASP is a novel investigational medicine designed to reduce serum urate (SU) levels in people with uncontrolled gout, potentially reducing harmful tissue urate deposits which when left untreated can lead to debilitating gout flares and joint deformity. NASP is administered every 4-weeks as a sequential, two-component, infusion therapy consisting of tolerogenic nanoencapsulated sirolimus (NAS) which mitigates the formation of anti-drug antibodies (ADAs) and a uricase, pegadricase (P), which reduces serum uric acid.

NASP 是一种新型研究性药物，旨在降低痛风控制不佳患者的血清尿酸 (SU) 水平，可能减少有害的组织尿酸沉积，若不加以治疗可能导致虚弱的痛风发作和关节变形。NASP 每 4 周施用一次，是一种序贯两组分输注疗法，包含耐受性纳米封装西罗莫司 (NAS)，可减轻抗药物抗体 (ADAs) 的形成，以及降低血清尿酸的尿酸酶聚乙二醇化尿酸酶 (P)。

ADAs develop due to unwanted immune responses to biologic medicines, reducing their efficacy and tolerability, which remains an issue across multiple therapeutic modalities and disease states including uncontrolled gout..

由于对生物药物产生不必要的免疫反应，导致抗药抗体（ADAs）的产生，降低了这些药物的疗效和耐受性。这一问题在多种治疗方式和疾病状态中仍然存在，包括难治性痛风。

About VONJO

关于VONJO

(pacritinib)

(帕克替尼)

VONJO is a kinase inhibitor that is indicated in the US for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10

VONJO 是一种激酶抑制剂，在美国适用于治疗血小板计数低于 50 × 10 的中危或高危原发性或继发性（真性红细胞增多症后或原发性血小板增多症后）骨髓纤维化成人患者。

/L. This indication is approved under accelerated approval based on spleen volume reduction. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

/L. 该适应症是基于脾脏体积缩小的加速批准。该适应症的持续批准可能取决于在确证性试验中对临床益处的验证和描述。

About VEXAS

关于VEXAS

VEXAS syndrome is a disease that causes inflammatory and hematologic (blood) manifestations. The syndrome is caused by mutations in the

VEXAS综合征是一种导致炎症和血液学表现的疾病。该综合征是由以下因素引起的突变：

UBA1

泛素样修饰物激活酶1

gene of blood cells and acquired later in life. The condition is not genetically inherited.

血细胞基因后天获得，这种情况并非遗传所致。

About Sobi

关于Sobi

Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across

Sobi是一家全球生物制药公司，致力于释放突破性创新的潜力，改变罕见病患者的日常生活。Sobi在全球拥有约1,900名员工。

Europe

欧洲

，

North America

北美

, the

，这个

Middle East

中东地区

，

Asia